CN103533949B - 作为缺血性脑损伤的有效神经保护剂并用于治疗疼痛的psd-95的高亲和力的二聚抑制剂 - Google Patents

作为缺血性脑损伤的有效神经保护剂并用于治疗疼痛的psd-95的高亲和力的二聚抑制剂 Download PDF

Info

Publication number
CN103533949B
CN103533949B CN201280023754.8A CN201280023754A CN103533949B CN 103533949 B CN103533949 B CN 103533949B CN 201280023754 A CN201280023754 A CN 201280023754A CN 103533949 B CN103533949 B CN 103533949B
Authority
CN
China
Prior art keywords
peptide
psd
linker
cpp
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280023754.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN103533949A (zh
Inventor
A·巴赫
K·斯特罗姆戈德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Københavns Universitet
Original Assignee
Københavns Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Københavns Universitet filed Critical Københavns Universitet
Publication of CN103533949A publication Critical patent/CN103533949A/zh
Application granted granted Critical
Publication of CN103533949B publication Critical patent/CN103533949B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201280023754.8A 2011-05-13 2012-05-11 作为缺血性脑损伤的有效神经保护剂并用于治疗疼痛的psd-95的高亲和力的二聚抑制剂 Active CN103533949B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161485898P 2011-05-13 2011-05-13
EP11165994 2011-05-13
US61/485,898 2011-05-13
EP11165994.2 2011-05-13
PCT/EP2012/058762 WO2012156308A1 (en) 2011-05-13 2012-05-11 High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain

Publications (2)

Publication Number Publication Date
CN103533949A CN103533949A (zh) 2014-01-22
CN103533949B true CN103533949B (zh) 2015-11-25

Family

ID=44367299

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280023754.8A Active CN103533949B (zh) 2011-05-13 2012-05-11 作为缺血性脑损伤的有效神经保护剂并用于治疗疼痛的psd-95的高亲和力的二聚抑制剂

Country Status (13)

Country Link
EP (1) EP2707014B1 (enExample)
JP (1) JP6084207B2 (enExample)
KR (1) KR102046830B1 (enExample)
CN (1) CN103533949B (enExample)
AU (1) AU2012257774C1 (enExample)
BR (1) BR112013029206B1 (enExample)
CA (1) CA2833515C (enExample)
DK (1) DK2707014T3 (enExample)
ES (1) ES2544573T3 (enExample)
IL (1) IL228893B (enExample)
PL (1) PL2707014T3 (enExample)
SG (1) SG194717A1 (enExample)
WO (1) WO2012156308A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3074032B1 (en) 2013-12-01 2018-12-26 University of Copenhagen Fatty acid derivatives of dimeric inhibitors of psd-95
CN103804500B (zh) * 2014-01-22 2015-12-30 广州军区广州总医院 用于治疗慢性疼痛的多肽
EP3757134B1 (en) * 2014-05-28 2024-03-06 NoNO Inc. Chloride salt of tat-nr2b9c
EP3650460A4 (en) * 2017-07-05 2021-03-17 Biocells (Beijing) Biotech Co., Ltd. PHARMACEUTICAL SALT OF A POLYPEPTID AND ITS USES
EA202090802A1 (ru) 2017-09-30 2020-08-05 Биоселз (Бейдзин) Биотек Ко., Лтд. Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью
US12077495B2 (en) 2018-02-02 2024-09-03 Københavns Universitet Compounds for the treatment of acute brain injury
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
CN110787284A (zh) * 2019-11-23 2020-02-14 胡书群 一种治疗缺血性脑损伤的混合小肽tat-shc及其应用
KR20220117914A (ko) * 2019-12-20 2022-08-24 피와이씨 테라퓨틱스 리미티드 신규 세포 전달 방법
CN111285923B (zh) * 2020-03-05 2023-02-03 成都奥达生物科技有限公司 一种psd-95抑制剂
US20240301003A1 (en) * 2021-01-08 2024-09-12 Nono Inc. Plasmin-resistant peptides for improved therapeutic index
TW202306965A (zh) 2021-05-12 2023-02-16 哥本哈根大學 Ｐｓｄ－９５抑制劑及其用途
CN114533874B (zh) * 2022-01-27 2023-12-29 北京和舆医药科技有限公司 Psd-95 gk结构域作为神经保护靶点的用途
CN121079099A (zh) * 2023-04-26 2025-12-05 深圳信立泰药业股份有限公司 一种psd-95结构域抑制剂、其制备方法及其用途
WO2025051130A1 (zh) * 2023-09-07 2025-03-13 湖南中晟全肽生物科技股份有限公司 作为神经保护剂的药用化合物及其应用
CN117164725B (zh) * 2023-09-07 2024-05-10 湖南中晟全肽生物科技股份有限公司 一种突触后密度蛋白-95抑制剂多肽
CN117903259B (zh) * 2023-09-07 2024-09-20 湖南中晟全肽生物科技股份有限公司 一种psd-95抑制剂及其用途
WO2025215348A1 (en) * 2024-04-08 2025-10-16 The Boots Company Plc Skin wound treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059597A1 (en) * 1999-06-02 2005-03-17 Michael Tymianski Method of reducing injury to mammalian cells
WO2008008348A2 (en) * 2006-07-11 2008-01-17 Arbor Vita Corporation Method and compositions for treating stroke with fever
WO2010004003A2 (en) * 2008-07-09 2010-01-14 University Of Copenhagen Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090285780A1 (en) 2006-05-24 2009-11-19 Chyi Lee Peg linker compounds and biologically active conjugates thereof
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059597A1 (en) * 1999-06-02 2005-03-17 Michael Tymianski Method of reducing injury to mammalian cells
WO2008008348A2 (en) * 2006-07-11 2008-01-17 Arbor Vita Corporation Method and compositions for treating stroke with fever
WO2010004003A2 (en) * 2008-07-09 2010-01-14 University Of Copenhagen Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《蛋白质的PEG化学修饰》;张继朋;《科技资讯》;20091231(第34期);116-117 *

Also Published As

Publication number Publication date
BR112013029206B1 (pt) 2021-05-04
CN103533949A (zh) 2014-01-22
CA2833515A1 (en) 2012-11-22
JP2014514365A (ja) 2014-06-19
ES2544573T3 (es) 2015-09-01
KR20140038435A (ko) 2014-03-28
EP2707014B1 (en) 2015-06-17
CA2833515C (en) 2017-11-28
BR112013029206A2 (pt) 2017-02-14
SG194717A1 (en) 2013-12-30
KR102046830B1 (ko) 2019-11-20
EP2707014A1 (en) 2014-03-19
IL228893B (en) 2018-01-31
IL228893A0 (en) 2013-12-31
JP6084207B2 (ja) 2017-02-22
AU2012257774A1 (en) 2013-11-07
AU2012257774B2 (en) 2016-07-28
DK2707014T3 (en) 2015-09-14
PL2707014T3 (pl) 2015-12-31
AU2012257774C1 (en) 2016-11-03
WO2012156308A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
CN103533949B (zh) 作为缺血性脑损伤的有效神经保护剂并用于治疗疼痛的psd-95的高亲和力的二聚抑制剂
CA2862391C (en) Stabilized antiviral fusion helices
ES2349743T3 (es) Derivados de la il-21.
JP7213811B2 (ja) 新規なステープルペプチドおよびその使用
US20230287051A1 (en) Inhibitors of complement factor c3 and their medical uses
JP2014513066A (ja) 抗新生物及び抗血管新生活性を有する環状ペプチド
US9139615B2 (en) High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
JP6952320B2 (ja) 新規ｎｋ３受容体アゴニスト
US10562935B2 (en) Stapled peptides and uses thereof
US20230174582A1 (en) Vipr2 antagonist peptide
CN117120459A (zh) 抗感染双环肽配体
US9408888B2 (en) High affinity bivalent helically constrained peptide against cancer
Caceres 3. CHAPTER 3 Engineering of an Anti-Inflammatory Peptide Based on the Disulfide-Rich Linaclotide Scaffold
Parlak Peptide-based drug systems

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant